Inflammatory Bowel Disease (IBD) is characterized by chronic inflammation of the gastrointestinal tract. The two major forms of IBD are Crohn`s Disease (CD) and Ulcerative Colitis (UC). Both have a chronic relapsing disease course and are often diagnosed during adolescence and young adulthood with approximately 20% of patients diagnosed before the age of 20 years. But the incidence of IBD in the paediatric population is rising with 10 per 100,000 children in the United States and Canada.
From 2-5 June 2021, the 6th World Congress of Paediatric Gastroenterology, Hepatology and Nutrition (WCPGHAN) will take place as a fully virtual event. BÜHLMANN will be present with a virtual booth sharing the product portfolio for diagnosis and therapeutic monitoring of IBD patients:
Calprotectin is the best marker for IBD diagnosis and therapy follow up in IBD and is useful to support quality of life of children through improved patient management. The easy-to-use IBDoc® home test allows for measuring calprotectin at patient home. It is a modern tool which helps to empower children and their parents to manage the chronic disease. It can also be embedded into patient support programmes.
Another core element by BÜHLMANN to support paediatric patients is the Quantum Blue® TDM portfolio with rapid tests for Infliximab and Adalimumab drug levels and their antibodies. This in combination with the control over inflammatory status by calprotectin is the most comprehensive diagnostic solution available today.
Visit us on our virtual booth at WCPGHAN 2021 from 2-5 June 2021!